Entero Healthcare [ENTERO] vs Welcure Drugs [WELCURE] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Entero Healthcare Solutions wins in 8 metrics, Welcure Drugs & Pharmaceuticals Ltd. wins in 10 metrics, with 0 ties. Welcure Drugs & Pharmaceuticals Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Entero Healthcare Solutions | Welcure Drugs & Pharmaceuticals Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 48.93 | 1.30 | Welcure Drugs & Pharmaceuticals Ltd. |
| Price-to-Book Ratio | 3.11 | 0.28 | Welcure Drugs & Pharmaceuticals Ltd. |
| Debt-to-Equity Ratio | 24.63 | 91.72 | Entero Healthcare Solutions |
| PEG Ratio | 5.72 | 0.01 | Welcure Drugs & Pharmaceuticals Ltd. |
| EV/EBITDA | 28.71 | 2.81 | Welcure Drugs & Pharmaceuticals Ltd. |
| Profit Margin (TTM) | 1.87% | 12.21% | Welcure Drugs & Pharmaceuticals Ltd. |
| Operating Margin (TTM) | 3.40% | 12.24% | Welcure Drugs & Pharmaceuticals Ltd. |
| EBITDA Margin (TTM) | 3.40% | 12.24% | Welcure Drugs & Pharmaceuticals Ltd. |
| Return on Equity | 5.36% | 2.12% | Entero Healthcare Solutions |
| Return on Assets (TTM) | 3.51% | 0.81% | Entero Healthcare Solutions |
| Free Cash Flow (TTM) | $-881.80M | $-2.22B | Entero Healthcare Solutions |
| 1-Year Return | -4.75% | -75.00% | Entero Healthcare Solutions |
| Price-to-Sales Ratio (TTM) | 0.91 | 0.10 | Welcure Drugs & Pharmaceuticals Ltd. |
| Enterprise Value | $58.10B | $1.26B | Entero Healthcare Solutions |
| EV/Revenue Ratio | 0.97 | 0.34 | Welcure Drugs & Pharmaceuticals Ltd. |
| Gross Profit Margin (TTM) | 10.11% | N/A | N/A |
| Revenue per Share (TTM) | $1,383 | $2 | Entero Healthcare Solutions |
| Earnings per Share (Diluted) | $25.83 | $0.23 | Entero Healthcare Solutions |
| Beta (Stock Volatility) | -0.79 | -1.80 | Welcure Drugs & Pharmaceuticals Ltd. |
Entero Healthcare Solutions vs Welcure Drugs & Pharmaceuticals Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Entero Healthcare Solutions | -1.26% | 0.29% | -5.86% | 12.11% | 12.06% | -0.64% |
| Welcure Drugs & Pharmaceuticals Ltd. | -3.70% | 0.00% | -10.34% | -3.70% | -45.83% | -38.10% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Entero Healthcare Solutions | -4.75% | -1.12% | -1.12% | -1.12% | -1.12% | -1.12% |
| Welcure Drugs & Pharmaceuticals Ltd. | -75.00% | -25.00% | 17.39% | -77.50% | 50.00% | -30.77% |
Performance & Financial Health Analysis: Entero Healthcare Solutions vs Welcure Drugs & Pharmaceuticals Ltd.
| Metric | ENTERO | WELCURE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹54.69B | ₹370.78M |
| Market Cap Category | Mid cap | Small cap |
| 10 Day Avg. Volume | 76,067 | 13,383,901 |
| 90 Day Avg. Volume | 89,093 | 10,165,552 |
| Last Close | ₹1,122.40 | ₹0.26 |
| 52 Week Range | ₹944.00 - ₹1,390.00 | ₹0.23 - ₹1.44 |
| % from 52W High | -19.25% | -82.00% |
| All-Time High | ₹1,584.25 (Nov 04, 2024) | ₹25.00 (Sep 19, 2005) |
| % from All-Time High | -29.15% | -98.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.26% | -1.00% |
| Quarterly Earnings Growth | 0.09% | 1.57% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.12% |
| Operating Margin (TTM) | 0.03% | 0.12% |
| Return on Equity (TTM) | 0.05% | 0.02% |
| Debt to Equity (MRQ) | 24.63 | 91.72 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹405.79 | ₹1.09 |
| Cash per Share (MRQ) | ₹37.37 | ₹0.02 |
| Operating Cash Flow (TTM) | ₹-1,784,990,000 | ₹-2,249,340,000 |
| Levered Free Cash Flow (TTM) | ₹948.20M | ₹21.70M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Entero Healthcare Solutions vs Welcure Drugs & Pharmaceuticals Ltd.
| Metric | ENTERO (Apr 24, 2026) | WELCURE (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 48.93 | 1.30 |
| Forward P/E | 28.42 | N/A |
| PEG Ratio | 5.72 | 0.01 |
| Price to Sales (TTM) | 0.91 | 0.10 |
| Price to Book (MRQ) | 3.11 | 0.28 |
| Market Capitalization | ||
| Market Capitalization | ₹54.69B | ₹370.78M |
| Enterprise Value | ₹58.10B | ₹1.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.97 | 0.34 |
| Enterprise to EBITDA | 28.71 | 2.81 |
| Risk & Other Metrics | ||
| Beta | -0.79 | -1.80 |
| Book Value per Share (MRQ) | ₹405.79 | ₹1.09 |
Financial Statements Comparison: Entero Healthcare Solutions vs Welcure Drugs & Pharmaceuticals Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | ENTERO (2025) | WELCURE (2025) |
|---|---|---|
| Revenue/Sales | 50.65B | 245.50M |
| Cost of Goods Sold | 46.09B | 205.03M |
| COGS % of Revenue | 91.0% | 83.5% |
| Gross Profit | 4.56B | 40.47M |
| Gross Margin | 9.0% | 16.5% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 1.42B | 9.61M |
| Operating Margin | 2.8% | 3.9% |
| EBITDA | 2.07B | -9.41M |
| EBITDA Margin | 4.1% | -3.8% |
| Pre-Tax Income | 1.39B | 27.80M |
| Pre-Tax Income % of Revenue | 2.7% | 11.3% |
| Income Tax | 313.05M | 6.10M |
| Income Tax % of Revenue | 0.6% | 2.5% |
| Net Income (Profit) | 1.07B | 21.70M |
| Profit Margin | 2.1% | 8.8% |
Balance Sheet & Liquidity Metrics
| Metric | ENTERO (2025) | WELCURE (2025) |
|---|---|---|
| Cash & Equivalents | 2.29B | 1.28M |
| Total Current Assets | 20.76B | 1.82B |
| Total Current Assets % of Revenue | 41.0% | 741.9% |
| Total Current Liabilities | 8.45B | 412.69M |
| Total Current Liabilities % of Revenue | 16.7% | 168.1% |
| Long-Term Debt | 670.18M | 1.23B |
| Long-Term Debt % of Revenue | 1.3% | 501.8% |
| Total Shareholders Equity | 17.70B | 1.03B |
| Retained Earnings | 638.28M | -100.79M |
| Retained Earnings % of Revenue | 1.3% | -41.1% |
| Property, Plant & Equipment | 1.64B | N/A |
Cash Flow Statement Comparison
| Metric | ENTERO (2025) | WELCURE (2025) |
|---|---|---|
| Operating Cash Flow | -1.78B | -2.25B |
| Operating Cash Flow % of Revenue | -3.5% | -916.2% |
| Capital Expenditures | -103.73M | -170,000 |
| Free Cash Flow | -881.80M | -2.22B |
| FCF Margin | -1.7% | -904.5% |
| Debt Repayment | -458.22M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ENTERO | WELCURE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 43.51M | 1.24B |
| Float Shares | 14.37M | 6.63M |
| % Held by Insiders | 65.97% | 85.74% |
| % Held by Institutions | 12.55% | 0.00% |
| % Held by Public | 21.48% | 14.26% |
Dividend Analysis & Yield Comparison: Entero Healthcare Solutions vs Welcure Drugs & Pharmaceuticals Ltd.
| Metric | ENTERO | WELCURE |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |